Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3H2101
Thu, 23.05.2024
aap Implantate AG
Notice to the Holders of the Mandatory Convertible Bond 2023/2028
(ISIN: DE000A351ZH9 / WKN: A351ZH)
aap Implantate AG announces today that the resolution adopted in the vote held without a meeting from March 26, 2024, to March 28, 2024, to cancel the vesting period regarding the conversion of the bonds and to allow a first-time conversion ri [ … ]
Mon, 22.04.2024
aap Implantate AG
Sales increase by 5.6% compared to the same quarter of the previous year
Major order and parts of Q1 sales form strong basis for growth in Q2
Human clinical trial of the innovative antibacterial implant technology is progressing positively and opens up the possibility of an earlier conclusion
aap Implantate AG ("aap" or "Company") continued it [ … ]
Fri, 19.04.2024
aap Implantate AG
The premium to the current share price of EUR 0.8 amounted to 37.5%
The cash inflow will strengthen the company's own resources for the ongoing human clinical trial of the innovative antibacterial implant technology
aap Implantate AG ("aap" or "Company") successfully completed the 10% capital increase announced on March 18, 2024 with exclusion [ … ]
Wed, 03.04.2024
aap Implantate AG
86.03% of the nominal amount and the votes of all outstanding bonds participated in the vote
Approval by 100% of the votes cast
aap Implantate AG ("aap" or "Company") successfully completed the vote without a meeting of bondholders on an amendment to the terms and conditions of the Bonds with an approval of 100% of the votes cast and the nominal v [ … ]
Thu, 15.02.2024
aap Implantate AG
Silver: significant acceleration in patient recruitment with over 130 patients as of the end of January 2024.
Sales: very good start to the 2024 financial year
Start of MDR certification
In the past financial year, aap Implantate AG ("aap" or "Company") was able to significantly accelerate patient recruitment with the realignment of the world's f [ … ]
Wed, 10.01.2024
aap Implantate AG
EQS-Media / 10.01.2024 / 07:30 CET/CEST
With regard to its innovative antibacterial implant technology, aap was able to successfully accelerate recruitment in the ongoing human clinical trial with the adapted study design in the course of 2023 and has already successfully recruited more than 100 patients by 31 December 2023.
aap currently ass [ … ]
Tue, 09.01.2024
aap Implantate AG
aap Implantate AG (“aap”) announces the conclusion of a distribution agreement for its LOQTEQ® VA Radius System with a leading global spine and orthopedics company.
The distribution agreement for the LOQTEQ® VA Radius System, the top selling product of aap`s anatomical plates and screws portfolio, is exclusively distributed in the entire territory [ … ]
Mon, 30.10.2023
aap Implantate AG
Clinical trial: Visible acceleration with already more than 60 patients recruited since clinical trial resumption in April; completion of patient recruitment planned in 2024
BMBF funding: increase in total funding by around EUR 0.4 million to up to EUR 3.1 million underscores the strategic innovative character of aap's antibacterial silver coat [ … ]
Thu, 31.08.2023
aap Implantate AG
aap Implantate AG ("aap" or the "Company") announces that Mr. Jochen Rahner will succeed CFO Mr. Marek Hahn as Director Finance, IR and IT as of November 1, 2023. Mr. Rahner has over 20 years of financial experience in various functions and holds a degree in mechanical engineering. We are convinced that Mr. Rahner will confidently lead the areas of [ … ]
Mon, 14.08.2023
aap Implantate AG
Sales: Q2 at EUR 2.9 million (+8 % yoy) and H1 at EUR 5.9 million (+6 % yoy); all regions in Q2 above previous year with LATAM (Q2: +13 %; H1: +29 % yoy) and North America (Q2: +7 %; H1: +11 % yoy) as main growth drivers
EBITDA: improvement in Q2 (+21 %) with EUR ‑0.6 million (Q2/2022 corr.: EUR ‑0.7 million) and H1 (+13 %) with EUR ‑1.0 millio [ … ]